Evidence map›Paper›PMID 37841427›Full record

ArticleFrontiers in oncology2023

Donor/recipient origin of lung cancer after lung transplantation by DNA short tandem repeat analysis.

Julien De Wolf, Edouard Robin, Alexandre Vallee, Justine Cohen, Abdul Hamid, Antoine Roux, Morgan Leguen, Romane Beaurepere, Ivan Bieche, Julien Masliah-Planchon and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Julien De WolfDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Edouard RobinDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Alexandre ValleeDepartment of Clinical Research and Innovation Foch Hospital, Suresnes, France.
Justine CohenDepartment of Anatomopathology, Foch Hospital, Suresnes, France.
Abdul HamidDepartment of Pneumology, Foch Hospital, Suresnes, France.
Antoine RouxDepartment of Pneumology, Foch Hospital, Suresnes, France.
Morgan LeguenDepartment of Anesthesiology, Foch Hospital, Suresnes, France.
Romane BeaurepereGenetics Department, Curie Institut, Paris, France.
Ivan BiecheGenetics Department, Curie Institut, Paris, France.
Julien Masliah-PlanchonGenetics Department, Curie Institut, Paris, France.
Matthieu GlorionDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Yves AlloryDepartment of Anatomopathology, Foch Hospital, Suresnes, France.
Edouard SageDepartment of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France.
Foch lung transplant group
Hôpital Foch · FRInstitut Curie · FRUniversité de Versailles Saint-Quentin-en-Yvelines · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer is more common in posttransplant recipients than in the general population. The objective of this study was to examine the chimerism donor/recipient cell origin of graft cancer in recipients of lung transplant. Methods: A retrospective chart review was conducted at Foch Hospital for all lung transplantations from 1989 to 2020. Short tandem repeat PCR (STR-PCR) analysis, the gold standard technique for chimerism quantification, was used to determine the donor/recipient cell origin of lung cancers in transplant patients. Results: Fourteen (1.4%) of the 1,026 patients were found to have graft lung cancer after lung transplantation, and one developed two different lung tumors in the same lobe. Among the 15 lung tumors, 10 (67%) presented with adenocarcinoma, four (27%) with squamous cell carcinoma and one with small cell lung cancer. STR analysis showed that the origin of the cancer was the donor in 10 patients (71%), the recipient in three patients (21%), and was undetermined in one patient. Median time to diagnosis was 62 months. Conclusion: The prevalence of lung cancer in lung transplant recipients is very low. However, the results of our study showed heterogeneity of genetic alterations, with 21% being of recipient origin. Our results highlight the importance of donor selection and medical supervision after lung transplantation.

Indexed as

chimerismdesoxyribonucleic acid (DNA)donorlung cancerlung transplantation (LT)polymorphism chain reaction (PCR) transplantationshort tandem repeat (STR)STR

Identifiers

PMID37841427
PMCPMC10568626
OpenAlexW4387184083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.